Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Bezlotuxumab returned no results
Showing 1 to 3 of 3 results for bezlotoxumab

  1. Clostridioides difficile infection: antimicrobial prescribing (NG199)

    This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.

    Antimicrobial prescribing guideline
    Published
    23 July 2021
    View recommendations

    Sections for NG199

  2. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

    Evidence summary
    Published
    6 June 2017

  3. Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

    This guidance has been updated and replaced by NICE guideline NG199.

    Technology appraisal guidance
    Published
    25 September 2019